2022年9月22日 · These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations. Since the 2017 report from the European LeukemiaNet (ELN), 1 there has been substantial progress in our knowledge of acute myeloid leukemia (AML).

2022年9月22日 · The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators.

2022年9月8日 · In NPM1 -mutated and core-binding factor AML, quantitative polymerase chain reaction (PCR) or a droplet digital PCR is recommended to monitor measurable residual disease (MRD).

The most visible results of the ELN are the guidelines and management recommendations for virtually every leukemia and interdisciplinary speciality which have lain the groundwork for uniform definitions and standards required for common clinical trials and projects.

2023年5月9日 · Risk stratification in acute myeloid leukemia (AML) remains principle in survival prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) recommendations were recently published, with notable updates to risk group assignment.

2023年5月9日 · Risk stratification in acute myeloid leukemia (AML) remains principle in survival prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) recommendations were recently published, with notable updates to risk group assignment.

2017年1月26日 · The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML.

2024年12月26日 · The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

2023年4月11日 · We studied 1118 newly diagnosed AML patients (median age, 58 years; range, 18–86 years) who received cytarabine-based induction chemotherapy between 1999 and 2012 and compared ELN-2022 to the...

2024年11月6日 · In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570 newly diagnosed AML patients (median age, 56 years) treated with cytarabine-based intensive chemotherapy regimens.